By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bavarian Nordic A/S 

Vesterbrogade 149

Copenhagen    DK-1620  Denmark
Phone: 45-3326-8383 Fax: 45-3326-8380




Company News
Billion Dollar Biotech Bavarian Nordic (BAVA.CO) Ditches $86 Million U.S. IPO 4/14/2016 6:27:58 AM
Six Biotechs Start Out 2016 By Filing IPOs 1/5/2016 8:13:44 AM
Janssen Announces Collaboration With Bavarian Nordic (BAVA.CO) To Develop Vaccine For Chronic Human Papillomavirus (HPV) Infections 12/21/2015 9:07:40 AM
Bavarian Nordic (BAVA.CO), Janssen Pharmaceutical Strike $171 Million HPV Vaccine Pact 12/18/2015 8:48:01 AM
Bavarian Nordic (BAVA.CO) Announces Results Of A Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine In Patients With Advanced Cancers 11/3/2015 10:45:52 AM
Bavarian Nordic (BAVA.CO) Applauds Recommendations Outlined By U.S. Blue Ribbon Study Panel On Biodefense 10/28/2015 12:12:23 PM
Bavarian Nordic (BAVA.CO) Announces Expansion Of IMVAMUNE Orders From Canadian Government 10/28/2015 10:26:16 AM
Bavarian Nordic (BAVA.CO) Announces Initiation Of Safety And Immunogenicity Study Of Ebola Vaccine Regimen In Sierra Leone 10/9/2015 9:56:01 AM
Bavarian Nordic (BAVA.CO) Announces Initiation Of NCI-Sponsored Phase 2 Study Of PROSTVAC In Patients With Localized Prostate Cancer 7/24/2015 10:10:25 AM
Bavarian Nordic (BAVA.CO) Announces That The Oxford Vaccines Group Has Initiated A Phase II Study Of The Ebola Prime-Boost Vaccine Regimen Combining MVA-BN Filo And Janssen's Advac Technology 7/15/2015 9:10:09 AM